Ranking Invest

Alpine Immune Sciences, Inc.

Segmento: Healthcare Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Indicadores Básicos

Valor de Mercado

$ 4.46 Bi

IVR

0.04

IVR2

-0.04

Índices de Previsibilidade

Faturamento

0.38

Lucro

0.34

Margem

0.58

Índices de Tendência

Faturamento

7.00

Lucro

-1.05

Margem

2.02

Índices de Endividamento

DIV/PAT

-0.07

DIV/L4T

0.63

Dívida Líquida

-$ 23.36 Mi

Patrimônio Líquido

$ 332.70 Mi

L4T

-$ 36.84 Mi

MM4T

-126.33%

Dívidas
Dividendos
Cotação: $64.97

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre